The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Cerdelga eliglustat OrphanAdditional monitoring | Sanofi B.V. | Gaucher Disease | 🇪🇺 EU 2015-01-19 | Order → |
| Zontivity vorapaxar Additional monitoring | Merck Sharp Dohme Limited | Myocardial Infarction | 🇪🇺 EU 2015-01-19 | Order → |
| Otezla apremilast | Amgen Europe B.V. | Arthritis, Psoriatic; Psoriasis; Behcet Syndrome | 🇪🇺 EU 2015-01-15 | Order → |
| Sevelamer carbonate Winthrop (previously Sevelamer carbonate Zentiva) sevelamer carbonate | Sanofi Winthrop Industrie | Hyperphosphatemia; Renal Dialysis | 🇪🇺 EU 2015-01-15 | Order → |
| Cosentyx secukinumab | Novartis Europharm Limited | Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing | 🇪🇺 EU 2015-01-14 | Order → |
| Exviera dasabuvir Accelerated assessment | AbbVie Limited | Hepatitis C, Chronic | 🇪🇺 EU 2015-01-14 | Order → |
| Ofev nintedanib Accelerated assessment | Boehringer Ingelheim International GmbH | Idiopathic Pulmonary Fibrosis; Lung Diseases, Interstitial; Pulmonary Fibrosis; Scleroderma, Systemic | 🇪🇺 EU 2015-01-14 | Order → |
| Senshio ospemifene | Shionogi B.V. | Postmenopause | 🇪🇺 EU 2015-01-14 | Order → |
| Viekirax ombitasvir;paritaprevir;ritonavir | AbbVie Deutschland GmbH & Co. KG | Hepatitis C, Chronic | 🇪🇺 EU 2015-01-14 | Order → |
| Rasagiline ratiopharm rasagiline | Teva B.V. | Parkinson Disease | 🇪🇺 EU 2015-01-12 | Order → |
| Scenesse afamelanotide Exceptional circumstancesAdditional monitoring | Clinuvel Europe Limited | Protoporphyria, Erythropoietic | 🇪🇺 EU 2014-12-22 | Order → |
| Cyramza ramucirumab | Eli Lilly Nederland B.V. | Stomach Neoplasms | 🇪🇺 EU 2014-12-19 | Order → |
| Rixubis nonacog gamma | Baxalta Innovations GmbH | Hemophilia B | 🇪🇺 EU 2014-12-19 | Order → |
| Duavive oestrogens conjugated;bazedoxifene | Pfizer Europe MA EEIG | Postmenopause | 🇪🇺 EU 2014-12-16 | Order → |
| Lynparza olaparib | AstraZeneca AB | Ovarian Neoplasms; Breast Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | 🇪🇺 EU 2014-12-16 | Order → |
| Duloxetine Lilly duloxetine | Eli Lilly Nederland B.V. | Neuralgia; Diabetic Neuropathies; Depressive Disorder, Major | 🇪🇺 EU 2014-12-08 | Order → |
| Moventig naloxegol | Grunenthal GmbH | Constipation; Opioid-Related Disorders | 🇪🇺 EU 2014-12-07 | Order → |
| Trevicta (previously Paliperidone Janssen) paliperidone | Janssen-Cilag International NV | Schizophrenia | 🇪🇺 EU 2014-12-05 | Order → |
| Tadalafil Mylan tadalafil Generic | Mylan Pharmaceuticals Limited | Erectile Dysfunction | 🇪🇺 EU 2014-11-21 | Order → |
| Trulicity dulaglutide | Eli Lilly Nederland B.V. | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2014-11-21 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.